<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02726542</url>
  </required_header>
  <id_info>
    <org_study_id>2016p-000657</org_study_id>
    <nct_id>NCT02726542</nct_id>
  </id_info>
  <brief_title>Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents</brief_title>
  <official_title>Augmenting Growth Hormone to Ameliorate Nonalcoholic Fatty Liver Disease in Adolescents</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fatty liver disease is an increasing problem in overweight and obese young adults. The
      purpose of this study is to test the effect of growth hormone on liver fat in obese young
      adults ages 18-29y with increased liver fat.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-alcoholic fatty liver disease (NAFLD) is a significant health problem in obese
      adolescents. Obese children and adolescents have significant reductions in growth hormone
      secretion, and we hypothesize that augmenting growth hormone in this population will decrease
      liver fat. Growth hormone inhibits hepatic de novo lipogenesis, which is an important source
      of hepatic lipid. Patients with pituitary GH deficiency have a higher prevalence of NAFLD and
      non-alcoholic steatohepatitis (NASH) than the general population, and replacement of GH in
      these individuals reduces signs of liver damage. The purpose of this study is to test the
      hypothesis that growth hormone treatment will decrease liver fat quantity in young adults who
      begin the trial with more than 5% liver fat measured by magnetic resonance spectroscopy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2017</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in hepatic fat</measure>
    <time_frame>24 weeks</time_frame>
    <description>change in hepatic fat as measured by hydrogen magnetic resonance spectroscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in aspartate aminotransferase (AST)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in alanine aminotransferase (ALT)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gamma glutamyl transferase</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in visceral adipose tissue</measure>
    <time_frame>24 weeks</time_frame>
    <description>Change in visceral adipose tissue volume as measured by magnetic resonance imaging</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>NAFLD</condition>
  <arm_group>
    <arm_group_label>Growth hormone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Somatropin given by daily subcutaneous injection. Dose will begin at 1mg and be titrated based on insulin-like growth factor 1 (IGF-1) levels.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>(no study treatment - observation only)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>Norditropin (growth hormone) given by injection using a pen-device</description>
    <arm_group_label>Growth hormone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          1. Males and Females ages 18-29yo

          2. BMI ≥95th percentile and/or ≥30kg/m^2

          3. Hepatic fat ≥5% by hydrogen magnetic resonance spectroscopy (1H-MRS)

          4. IGF-1 standard deviation score (SDS) &lt; 0

        Exclusion criteria:

          1. Alcohol consumption of &gt;14 drinks per week (Females) or &gt;21 drinks per week (Males)

          2. Use of insulin or oral anti-diabetic medications, or hemoglobin A1c (HbA1c) &gt;7% or
             fasting glucose ≥126mg/dL

          3. Use of corticosteroid, gonadal steroids, or methotrexate ≤ 3 months prior to baseline
             visit

          4. Known diagnosis of alpha-1 antitrypsin deficiency, Wilson's disease, hemochromatosis,
             or autoimmune hepatitis

          5. hemoglobin &lt; 11.0 g/dL or weight &lt; 50kg

          6. aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2.5x upper limit
             of normal (ULN), total bilirubin &gt; ULN, positive hepatitis B surface antigen (sAg), or
             positive hepatitis C antibody

          7. Routine magnetic resonance imaging (MRI) exclusion criteria (including weight &gt;450
             pounds)

          8. Use of weight-loss medications or previous weight loss surgery

          9. Pregnant or breastfeeding, or, for sexually-active females, unwillingness to use an
             appropriate form of contraception during the study

         10. Known cirrhosis or clinical evidence of cirrhosis or portal hypertension on imaging or
             exam

         11. Use of growth hormone (GH) or growth hormone releasing hormone within the past 1 year

         12. Change in lipid lowering or anti-hypertensive medications within 3 months of screening

         13. Change in vitamin E or ursodiol &lt;6 months before screen; subjects on stable doses of
             Vitamin E and/or Ursodiol for ≥6 months will be eligible.

         14. History of malignancy or active malignancy

         15. History of hypopituitarism, head irradiation or any other condition or chronic illness
             known to affect the GH axis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>29 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Takara Stanley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takara Stanley, MD</last_name>
    <phone>617-726-5312</phone>
    <email>tstanley@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takara L. Stanley, MD</last_name>
      <phone>617-726-5312</phone>
      <email>tstanley@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 30, 2016</study_first_submitted>
  <study_first_submitted_qc>March 30, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2016</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Takara Stanley, M.D.</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>obesity</keyword>
  <keyword>adolescence</keyword>
  <keyword>fatty liver</keyword>
  <keyword>growth hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

